COASTAL: A PHASE 3 STUDY OF THE PI3Kδ INHIBITOR ZANDELISIB WITH RITUXIMAB (R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED INDOLENT NON‐HODGKIN’S LYMPHOMA (INHL)
Sign Up to like & getrecommendations! Published in 2021 at "Hematological Oncology"
DOI: 10.1002/hon.174_2880
Abstract: TPS7573Background: Patients (pts) with iNHL treated with front-line immunochemotherapy may benefit from an alternative, chemotherapy-free regimen at relapse. Zandelisib, a potent, selective, and st... read more here.
Keywords: immunochemotherapy; study pi3k; coastal phase; inhibitor zandelisib ... See more keywords